reference/2266318

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2266318

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase III\|Journal Article\|Multicenter Study\|Randomized Controlled Trial
endingPage	1093
issn	0923-7534
issueIdentifier	7
pageRange	1086-1093
publicationName	Annals of oncology : official journal of the European Society for Medical Oncology
startingPage	1086
bibliographicCitation	Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau' F, Scambia G; Multicenter Italian Trials in Ovarian Cancer invesitgators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol. 2003 Jul;14(7):1086–93. doi: 10.1093/annonc/mdg301. PMID: 12853351.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7e6035bff840f6ec05401ad5794e2999 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_003a02bf1c0c1100518449df5e776849 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2e5f0df5a2fdf0940764d19feeb9dacc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3cc325cb3d0b816edcc842d16396ab74 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d79b404e7ada5272320a2847a638341 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_61e31d04af1108448607056e22ea154a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d9ac1a90d98087b8157546d179965e06 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f872ca1df17e201afad3bd3d2d39035a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd4479a375cbca356894aeb5675c47c0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c5cbb227e6f41f060cb1730a3863930b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b943ada6b4f98a0825d7148939f57977
date	200307
identifier	https://pubmed.ncbi.nlm.nih.gov/12853351 https://doi.org/10.1093/annonc/mdg301
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1846 https://portal.issn.org/resource/ISSN/0923-7534
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients
discusses	http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0018387 http://id.nlm.nih.gov/mesh/M0026156 http://id.nlm.nih.gov/mesh/M0007867 http://id.nlm.nih.gov/mesh/M0024707
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D010051Q000188 http://id.nlm.nih.gov/mesh/D011837Q000494 http://id.nlm.nih.gov/mesh/D004999Q000494
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D013280Q000517 http://id.nlm.nih.gov/mesh/D009503Q000517 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D017239Q000009 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D004906 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D013921Q000139 http://id.nlm.nih.gov/mesh/D013921Q000517 http://id.nlm.nih.gov/mesh/D013280Q000139 http://id.nlm.nih.gov/mesh/D017239Q000008 http://id.nlm.nih.gov/mesh/D009061Q000473 http://id.nlm.nih.gov/mesh/D007262 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D016190Q000009 http://id.nlm.nih.gov/mesh/D016190Q000008 http://id.nlm.nih.gov/mesh/D009503Q000139
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10931 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8752 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10523 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2141 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID426756

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128288519

Total number of triples: 67.